-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

705.O3.6 705. Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy

Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, Lymphomas, non-Hodgkin lymphoma, elderly, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, B Cell lymphoma, Clinical Research, health outcomes research, Diseases, Therapies, aggressive lymphoma, therapy sequence, real-world evidence, Lymphoid Malignancies, registries, Technology and Procedures, Study Population, Human, imaging, Minimal Residual Disease
Monday, December 12, 2022: 10:30 AM-12:00 PM
393-396 (Ernest N. Morial Convention Center)
Moderators:
Michael D. Jain, MD, PhD, Moffitt Cancer Center and Olalekan O. Oluwole, MBBS, Vanderbilt Univeristy
Disclosures:
Oluwole: Kite, a Gilead Company: Research Funding; Janssen: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; TG Therapeutics: Consultancy; Curio Science: Consultancy; ADC Therapeutics: Consultancy; Nektar: Consultancy; Syncopation: Consultancy; Epizyme: Consultancy.
10:30 AM

Stefan K. Barta, MD1, Ariela Noy, MD2, Marcelo C Pasquini, MD, MS3, Naya He, MPH4*, Tiffany Hunt, MS5*, Carlos Litovich, MPH6*, Uroosa Ibrahim, MD, MBBS7*, Robert A. Baiocchi, MD, PhD8 and Richard F. Ambinder, MD, PhD9

1Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
3CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine,, Froedtert & The Medical College Cancer Ctr., Milwaukee, WI
4CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
5CIBMTR, Medical College of Wisconsin, Milwaukee, WI
6CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
7Department of Hematology and Oncology, Bone Marrow Transplantation and Cellular Therapy Program, Mount Sinai Hospital, New York, NY
8Department of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH
9Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

10:45 AM

Mariana Bastos-Oreiro, MD, PhD1*, Antonio Gutierrez, MD, PhD2*, Gloria Iacoboni, MD3*, Lucía López Corral, MD PhD4*, Juan Luis Reguera, MD5*, Nuria Martínez-Cibrian, MD6*, María José Terol, MD PhD7*, Ana Carolina Carolina Caballero Gonzalez, MD8*, Jaime Sanz, MD9*, Luisa Maria Guerra, MD10*, Pau Abrisqueta, MD, PhD11*, Gillen Oarbeascoa, MD12*, Javier Delgado13*, Rafael Hernani, MD14*, Alberto Mussetti15*, Ana Jimenez-Ubieto, MD, PhD16*, Juan-Manuel Sancho, MD, PhD17*, Anna Sureda18, Antonio Perez, MD, PhD19*, Pere Barba, MD, PhD20*, Mi Kwon, MD, PhD21* and Alejandro Martín García-Sancho, MD, PhD22*

1Servicio de Hematología y Hemoterapia, Hospital Gral. Univ. Gregorio Marañón, Madrid, Madrid, Spain
2Hematology Department, Hospital Universitario Son Dureta, Palma, Spain
3Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, WA, Spain
4Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain
5Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Sevilla, Spain
6Hematology, Hospital Clinic Barcelona, Barcelona, Spain
7Department of Hematology, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain
8Hematology Department, Hospital de la Santa Creu i Sant Pau, BARCELONA, Spain
9Avinguda Fernando Abril Martorell, Hospital Universitario La Fe, Valencia, Valencia, Spain
10Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
11Department of Hematology, Hospital Universitari Vall d´Hebron, Barcelona, Spain
12Department of Hematology, Hospital General Universitario Gregorio Marañón, Gregorio Marañon Health Research Institute, Madrid, Madrid, Spain
13Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío, Sevilla, Spain
14Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain
15Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, L'Hospitalet De Llobregat, Barcelona, Spain
16GELTAMO, Hospital Doce de Octubre, Madrid, Spain
17Clinical Hematology Department, Hospital Germans Trias i Pujol, Badalona, Spain
18Institut Català d'Oncologia, Hospital Duran i Reynals. Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Universitat de Barcelona, Barcelona, Spain
19Hemato-Oncology Pediatric Service, Hospital Universitario La Paz, Madrid, Spain
20Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
21Department of Hematology, Hospital General Universitario Gregorio Marañón, Gregorio Marañon Health Research Institute, Madrid, Spain
22Department of Hematology, Hospital Clínico Universitario de Salamanca, IBSAL, Salamanca, Spain

11:00 AM

Matthew A. Lunning, DO, FACP1, Hai-Lin Wang, MPH2*, Zhen-Huan Hu, MPH2*, Frederick L. Locke, MD3, Tanya Siddiqi, MD4, Caron A. Jacobson, MD5, Sairah Ahmed, MD6, David B. Miklos, MD, PhD7, Yi Lin, MD, PhD8, Brian T. Hill, MD, PhD9, Armin Ghobadi, MD10, Sattva S. Neelapu, MD11, Jason Westin, MD12, Harry Miao, MD, PhD2*, Shilpa Shahani, MD2*, Anik R. Patel, PhD2*, Clare Spooner, MBBS, BSc2*, Christine Fu, PhD2*, Hairong Xu, MD, PhD2* and Marcelo C Pasquini, MD, MS13

1University of Nebraska, Omaha, NE
2Kite, a Gilead Company, Santa Monica, CA
3Moffitt Cancer Center, Tampa, FL
4City of Hope National Medical Center, Duarte, CA
5Dana-Farber Cancer Institute, Boston, MA
6The University of Texas MD Anderson Cancer Center, Houston, TX
7Division of BMT and Cellular Therapy, Stanford University, Stanford, CA
8Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
9Cleveland Clinic Foundation, Cleveland, OH
10Washington University School of Medicine, Saint Louis, MO
11Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX
12Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
13Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

11:15 AM

Christopher J. Ferreri, MD1, Michelle A.T. Hildebrandt, PhD1, Hamza Hashmi, MD2, Leyla O. Shune, MD3, Joseph P. McGuirk, DO4, Douglas W. Sborov, MD5, Charlotte B Wagner, PharmD6*, M. Hakan Kocoglu, MD7, Shebli Atrash, MD8, Peter M. Voorhees, MD9, Jack Khouri, MD10, Danai Dima, MD10, Aimaz Afrough, MD11, Aishwarya Sannareddy, MBBS12*, Gary Simmons, DO13, James Davis, PharmD2*, Nilesh Kalariya1*, Lauren C. Peres, PhD, MPH14*, Melissa Alsina, MD**15, Frederick L. Locke, MD16, Surbhi Sidana, MD17, Doris K. Hansen, MD18, Krina Patel, MD, MSc19 and Omar Alexis Castaneda Puglianini, MD20

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematology/Medical Oncology, Medical University of South Carolina, Charleston, SC
3Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
4The University of Kansas Medical Center, Kansas City, KS
5Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
6University of Utah Huntsman Cancer Institute, Salt Lake City, UT
7University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
8Levine Cancer Institute, Charlotte, NC
9Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest Baptist, Charlotte, NC
10Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
11Division of Hematologic Malignancies and Cellular Therapy, Dept of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
12Division of Hematologic Malignancies, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX
13Virginia Commonwealth University Massey Cancer Center, Richmond, VA
14H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
15Moffitt Cancer Center, Tampa, FL
16Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
17Stanford University School of Medicine, Stanford, CA
18Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
19Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
20Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

11:30 AM

Jean Lemoine1*, Emmanuel Bachy, MD, PhD2*, Guillaume Cartron, MD, PhD3*, David Beauvais, MD4*, Thomas Gastinne, MD5*, Marie Thérèse Rubio, MD, PhD6*, Xavier Leleu, MD, PhD7, Mohamad Mohty, MD PhD8, René-Olivier Casasnovas, MD, PhD9*, Magalie Joris, MD10,11*, Cristina Castilla-LLorente, MD, PhD12,13*, Corinne Haioun, MD, PhD14,15, Olivier Hermine, MD, PhD16, Michael Loschi, MD, PhD17*, Sylvain Carras, MD, PhD18*, Pierre Bories, MD19*, Tom Fradon20*, Charles Herbaux21,22, Pierre Sesques, MD23*, Steven Le Gouill, MD, PhD24, Franck Morschhauser, MD25*, Catherine Thieblemont, MD, PhD26 and Roch Houot, Pr, MD, PhD27*

1Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Hemato-oncologie; Université de Paris, Paris, France
2Hematology Department, Hospices Civils de Lyon; Lymphoma Immuno-Biology (LIB) Team, Université Claude Bernard Lyon 1, Lyon, France
3Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France
4Department of Hematology, University Hospital of Lille, Lille, France
5Hematology Department, Nantes University Hospital, Nantes, France
6Hematology Department, University Hospital of Nancy, Vandoeuvre, France
7Department of Oncology, Hematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France
8Department of Haematology, Saint Antoine Hospital, Paris, France
9Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France
10Service d’Hématologie Clinique et Thérapie cellulaire, Centre Hospitalier Universitaire d’Amiens, Amiens, France
11CHU Amiens, Amiens, France
12Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France
13Department of Hematology and INSERM UMR 1030, Université Paris-Saclay, Gustave Roussy Cancer Campus Grand Paris, Paris, France
14Lymphoid Malignancies Department, Henri Mondor University Hospital/Assistance Publique-Hôpitaux de Paris (AP-HP)/Université Paris-Est Créteil (UPEC), Creteil, France
15Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil, France
16Clinical Hematology, Necker University Hospital, Paris, France
17Hematology department, CHU de Nice, Universite Cote d'Azur, Nice, France
18Centre Hospitalier Universitaire Grenoble, La Tronche, FRA
19Department of Hematology, Toulouse University Institute of Cancer, Toulouse, France
20Lymphoma Academic Research Organisation, Pierre-Benite, France
21CHU de Montpellier, Montpellier, France
22Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
23Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre Benite, France
24Service d'hématologie clinique, CHU de Nantes, Nantes, France
25Centre Hospitalier Régional Universitaire De Lille, Lille, FRA
26Department of Hemato-Oncology, Saint Louis Hospital, Paris, France
27Clinical Hematology, University Hospital Pontchaillou, Rennes Cedex, FRA

11:45 AM

Radhika Bansal, MBBS1*, Sikander Ailawadhi2, Jeremy T. Larsen3*, Morie A Gertz, MD1,4, Matthew A. Hathcock, M.S.5*, David Dingli, MD, PhD1, Prashant Kapoor, MD6, Taxiarchis Kourelis, MD1, Suzanne R. Hayman, MD1, Rahma M Warsame, MD6, Moritz Binder, MD, MPH1, Ricardo D Parrondo, MD7, Rafael Fonseca, MD8, P. Leif Bergsagel, MD9, Shaji K Kumar, MD6 and Yi Lin, MD, PhD6

1Division of Hematology, Mayo Clinic, Rochester, MN
2Division of Hematology, Mayo Clinic, Jacksonville, FL
3Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
4Division of Hematology, Department of Internal Medicine, Mayo Clinic, ROCHESTER, MN
5Department of Biostatistics, Mayo Clinic, Rochester, MN
6Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
7Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
8Department of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
9Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ

*signifies non-member of ASH